Exploring FDA-Approved COVID-19 Treatments: Ivermectin and Beyond

The current global pandemic has significantly impacted healthcare systems worldwide, leading to a renewed interest in understanding the available options for treating COVID-19. This article delves into the approved treatments by the Food and Drug Administration (FDA), specifically focusing on the status of Ivermectin and the evolving standards in prescribing.

Understanding FDA Approved Treatments for COVID-19

The recent COVID-19 pandemic has prompted numerous inquiries regarding FDA-approved treatments for the virus. While it is true that CBD may provide some relief in managing the effects of COVID-19, there is a distinct lack of evidence supporting its efficacy as a treatment. In contrast, Ivermectin has garnered significant attention due to its potential in combating the virus.

Introduction to Ivermectin: A Long-Standing FDA-Approved Drug

Ivermectin is a widely used antiparasitic drug that has been FDA-approved for treating parasitic infections such as onchocerciasis and strongyloidiasis since 1966. For over five decades, this drug has been safely prescribed and used in the United States, with tens of millions of people worldwide benefitting from its effectiveness. However, the FDA’s stance on its use for COVID-19 has evolved over time.

Off-Label Prescribing and the FDA's Role

Despite the FDA's initial approval for treating parasitic diseases, the agency has been cautious about extending its use for other conditions. Nonetheless, the practice of off-label prescribing is both legal and common in the medical field. Physicians can use any FDA-approved drug for purposes outside its original intended use based on their judgment. This practice has led to the widespread use of Ivermectin in treating COVID-19.

National Institute of Health (NIH) and the Ivermectin Controversy

The National Institute of Health (NIH) has recognized the potential of Ivermectin in treating COVID-19. On January 14, 2021, the NIH announced that Ivermectin could be used as an option for treating the virus. This decision was based on data presented by Dr. Paul Marik and Dr. Pierre Kory of the Frontline COVID-19 Critical Care Alliance (FLCCC) and Dr. Andrew Hill, a researcher and consultant to the World Health Organization (WHO).

The action by the NIH did not come without controversy, as the FDA, a politically sensitive body, issued a statement advising against the use of Ivermectin for treating COVID-19. This statement, despite its long history of approving the drug for other uses, has sparked debate among medical professionals and the public.

Cost and Accessibility

One of the reasons for the ongoing debate is the low cost of Ivermectin. A single course of the medication can cost as little as $2.25, making it an affordable option for many. This affordability, combined with the growing body of evidence from researchers and practitioners, has contributed to its increasing use in managing COVID-19.

For those seeking further information on the I-MASK Plus prophylaxis and outpatient treatment protocol for COVID-19, you can visit the FLCCC’s official website for more detailed guidelines.

Final Thoughts

The landscape of FDA-approved treatments for COVID-19 remains dynamic, with Ivermectin emerging as a potential option. It is crucial for healthcare providers and patients to stay informed, conduct their own research, and make informed decisions.

Do your own research and make up your own mind!

With Warm Aloha,
Tim